TNF and psoriasis: In a randomized clinical trial, the effects of ustekinumab (IL-12/IL-23 inhibitor), etanercept (TNF-α inhibitor), or cyclosporine were compared regarding the heart function and oxidative stress in patients with psoriasis [90].